Business

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis

Financial Post · October 15, 2026 at 1:04 a.m.

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, ma

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis

More from Financial Post

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation

Deep Drilling Intersects Epithermal Mineralisation 1 km Below Proprietary Pit at Peak Hill

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

Brookfield Renewable Corporation Shareholders Approve Proposed Corporate Simplification

More in Business

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation

Deep Drilling Intersects Epithermal Mineralisation 1 km Below Proprietary Pit at Peak Hill

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

Brookfield Renewable Corporation Shareholders Approve Proposed Corporate Simplification

Brookfield Infrastructure Partners L.P. Unitholders Approve Proposed Corporate Simplification

Dream Industrial Real Estate Investment Trust Announces Offering of C$300 Million Senior Unsecured Debentures, Series I